Dr. William May is Clinical Director of Pediatric Hematology Oncology and the Director of the Leukemia and Lymphoma Section of the Division of Pediatric Hematology Oncology at The David Geffen School of Medicine at UCLA. He has been board certified in Pediatric Hematology Oncology since 1992.
Dr. May earned his Bachelor's degree at the University of California Davis and his MD from the Saint Louis University School of Medicine. His Pediatric Internship was at UCLA and he completed his residency years at UCSF. His Pediatric Hematology Oncology Fellowship was at UCLA.
Prior to his present appointment, Dr. May held a faculty position at the University of Alabama School of Medicine and the Children's Hospital of Alabama from 1996-2003. From 2003-2016, he was on faculty at the Keck School of Medicine at USC and on staff at Children's Hospital Los Angeles.
Dr. May's clinical interests are in Hematologic Malignancies of Childhood and Adolescence. He is UCLA Principal Investigator for the Children's Oncology Group (COG). He is responsible for the conduct of COG clinical trials at UCLA.
Medical Board Certification
- Solid Tumors
- Kang, H.G., Jenabi, J.M., Zhang, J., Keshelava, N., Shimada, H., May, William A., Ng, T., Reynolds, C.P., Triche, T.J., Sorensen, P.H. E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Research, (2007) 67(7):3094-105. PMCID: PMC3906735
- Zwerner, J.P., Joo, J., Warner, K.L., Christensen, L., Hu-Lieskovan, S.,Triche, T.J., and May, W. A. The EWS/FLI1 Oncogenic Transcription Factor Deregulates GLI1. Oncogene, (2008) 27(23): 3282 - 3291.
- Jay Joo, Laura Christensen, Kegan Warner, Leith States, Hyung Kang, Kieuhoa Vo, Elizabeth Lawlor, and May, William A. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing Tumors. PLoS ONE, (2009) Oct 27;4(10): e7608. PMCID: PMC2763206
- Luo, P., Yang, X., Ying, M., Chaudhry, P., Wang, A., Shimada, H., May, W. A., Adams, Mock, D., Triche, T.J., Qiaojun He, and L. Wu. Retinoid-suppressed phosphorylation of RAR mediates the differentiation pathway of osteosarcoma cells. Oncogene, (2010) 29: 2772-2783. PMCID: PMC3277667
- Wu, L., Ying, M., Liu, G., Shimada, H., May, W. A., He, Q., and Adams, G. Human osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity. Oncogene (2013) 32, 4252–4263; doi:10.1038/onc.2012.438; published online 8 October 2012. PMCID: PMC3947577
- Christensen, L., Joo, J., Lee, S., Wai, D., Triche, T. J., and May, William A. FOXM1 is an Oncogenic Mediator in Ewing Sarcoma. PLoS ONE, (2013) Jan 24: 8(1): e54556. PMCID: PMC3554707
- Venkatramani, R., Malogolowkin, M., Davidson, T. B., May, W., Sposto, R., L. Mascarenhas. A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors. PLoS ONE, (2013) Jul 22; 8(7): e68416. PMCID: PMC3718768
- Holly, L., Jubran, R.F., Wang, L., Kipp, B.R., and May, William A. Simultaneous Colonic Adenocarcinoma and Medulloblastoma in a 12 year old with Biallelic Deletions in PMS2. Journal of Pediatrics, (2013). Aug;163(2): 601-3. PMCID: PMC3862975
- May, William A., Grigoryan, R.S., Keshelava, N., Cabral, D.J., Christensen, L.L., Jenabi, J., Lingyun, J., Lawlor, E.R. and Reynolds, C.P. Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines. PLoSONE (2013), December 02, DOI: 10.1371/journal.pone.0080060. PMCID: PMC3846563
- 2018 Los Angeles Magazine Top Doctors
- 2017 Excellence in Teaching Award, Pediatric Hematology Oncology